Ionis Pharmaceuticals, Inc.

797 articles with Ionis Pharmaceuticals, Inc.

• Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year

  9/25/2019

   Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California's life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year.

• CLSA Names 2019 Pantheon DiNATM Award Winners, Recognizing Advancements in California Life Sciences

  9/25/2019

  California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced the 2019 Pantheon DiNATM Awards slate of honorees.

• 

  Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  9/23/2019

  50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.

• Ionis Pharmaceuticals to present at upcoming investor conferences - Aug. 28, 2019

  8/28/2019

  Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following investor conferences

• Ionis licenses hepatitis B program to GSK

  8/27/2019

  Ionis Pharmaceuticals, Inc. announced that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.

• 

  Akcea and Ionis Gear Up for Second Attempt at Getting Waylivra FDA Approval

  8/8/2019

  Waylivra was rejected by the FDA last year but gained approval in Europe in May. The publication of final Phase III data in the New England Journal of Medicine could support a potential bid for regulatory approval in the U.S.

• New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome

  8/7/2019

  Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., announced that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM).

• Ionis Reports Second Quarter 2019 Financial Results

  8/7/2019

  Ionis Pharmaceuticals, Inc. reported its financial results for the second quarter and year-to-date 2019 and recent business highlights.

• Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast

  7/30/2019

  Webcast scheduled for Wednesday, August 7th at 11:30 a.m. Eastern Time

• Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference

  6/18/2019

  Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the BMO Prescription for Success Healthcare Conference at 9:20 a.m. ET on Tuesday, June 25, 2019 in New York, NY.

• Ionis announces appointment of Joan E. Herman to its board of directors

  6/12/2019

   Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC

• Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders

  6/6/2019

  Ionis Pharmaceuticals, Inc. announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.

• Ionis reports first quarter 2019 financial results

  5/9/2019

  Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.

• Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients

  5/6/2019

  Ionis Pharmaceuticals, Inc. unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases.

• Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

  5/1/2019

  Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others

• Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast

  4/25/2019

  Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time

• Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders

  4/8/2019

  Ionis Pharmaceuticals, Inc. announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.

• Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors

  3/25/2019

  Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors.

• 

  BioSpace's Global Biopharma Roundup: March 7

  3/7/2019

  Biotech and pharma companies from across the globe share data and news in a weekly roundup.

• PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

  3/4/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA